Deep 6 AI vs Triomics
Breadth against depth in trial matching. Deep 6 covers the whole trial lifecycle across therapeutic areas, reading unstructured notes, pathology, genomics and laboratory data to match patients and sites, and it quantifies how much decisive eligibility information lives in the unstructured half of the record. Triomics is oncology only and better evidenced for it, with peer reviewed validation in a recognised journal, every match traced back to the pathology and biomarker behind it, and the deepest workflow integration in this category. For a cancer centre where oncology trials are the programme, Triomics is doing the harder version of the job and can show its working. For a health system running trials across several specialties, buying an oncology tuned platform leaves the rest uncovered. Neither publishes how often an eligible patient never surfaces.
- It reads the whole chart with an oncology tuned platform and traces every match back to the pathology and biomarker that produced it, so a coordinator can check the reasoning rather than trust a score.
- Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in this category.
- The output lands where the oncology team already works rather than in a separate screening tool, which is the deepest integration position here.
- Coverage is not confined to oncology, so a health system running trials across several therapeutic areas gets one platform rather than a cancer specific one.
- It quantifies how much decisive eligibility information sits in unstructured data, which is the argument for reading notes rather than filtering codes.
- Functional breadth spans feasibility and cohort building as well as matching, so sponsors and sites use the same system.
Side by Side
| Axis | D Deep 6 AI |
T Triomics |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both should be asked for the false negative rate on eligibility screening, which neither publishes and which is the only measure of whether a matching system works: a patient who was eligible and never appeared costs a trial an enrolment and costs the patient an option, invisibly. Triomics publishes no security attestation or trust centre. Deep 6 publishes no attestation scoped to the platform, no business associate terms and no governance framework. Trial matching also inherits documentation bias, so patients with sparse or fragmented records are systematically less likely to be found regardless of their eligibility.